Jaxteran (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 cellular pathway, which enhances the production of antioxidant proteins and reduces inflammatory signaling. This dual action provides neuroprotective benefits in multiple sclerosis and anti‑inflammatory effects in psoriasis, helping to control disease progression.

The specific dose of Jaxteran is determined by the prescribing clinician based on the patient’s condition, disease severity, and individual response. Healthcare providers follow approved dosing guidelines and may adjust the regimen according to therapeutic goals and safety monitoring.

Safety data for dimethyl fumarate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To request Jaxteran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with injectable disease‑modifying therapies, Jaxteran offers an oral administration route and targets the Nrf2 pathway rather than cytokine inhibition. It provides a favorable convenience profile but shares similar safety considerations such as lymphopenia, requiring regular monitoring.

Jaxteran should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Jaxteran is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken at the same time each day as directed by the prescriber.

The most serious risks include progressive multifocal leukoencephalopathy (PML), severe liver injury, and life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, liver dysfunction, and any hypersensitivity symptoms.

Jaxteran is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, and it should be avoided in individuals with active severe infections or those receiving live vaccines. Clinicians should also exercise caution in patients with significant lymphopenia or hepatic impairment.